Enterprise Value
34.39M
Cash
76.72M
Avg Qtr Burn
-15.81M
Short % of Float
24.30%
Insider Ownership
1.74%
Institutional Own.
40.24%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NeoCart® (Autologous chondrocyte-derived neocartilage) Details Articular cartilage defects in the knee | Phase 3 Initiation | |
COVAXIN (BBV152) Details COVID-19, Infectious disease | Phase 2/3 Data readout | |
OCU400 Details Retinitis Pigmentosa | Phase 1/2 Update |